Given that tumors with high NRF2 expression were associated with better survival outcomes and enriched inflammation- and immune-related gene sets in ER-positive/HER2-negative subtype, we hypothesized that non-cancer cells in the tumor microenvironment may be involved in NRF2 expression of a bulk tumor. The gene discussed is ESR1; the disease is cancer.